Intellia Therapeutics Inc (NTLA) Stock Could Soon Reward Patient Investors

Intellia Therapeutics Inc (NASDAQ: NTLA) is -2.89% lower on its value in year-to-date trading and has touched a low of $22.67 and a high of $47.48 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $28.23 in the last trading session, with the day’s gains setting it 1.38%.

Currently trading at $29.61, the stock is 14.76% and 4.18% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing 4.89% at the moment leaves the stock -14.57% off its SMA200. NTLA registered -27.96% loss for a year compared to 6-month loss of -25.06%. The firm has a 50-day simple moving average (SMA 50) of $37.00 and a 200-day simple moving average (SMA200) of -$4.02.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 5.19% gain in the last 1 month and extending the period to 3 months gives it a 18.63%, and is 19.20% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.89% over the week and 5.83% over the month.

Profit margin for the company is -893.34%. Distance from 52-week low is 30.64% and -37.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-40.61%).

Intellia Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$1.45 with sales reaching $12.82M over the same period.The EPS is expected to grow by 12.40% this year, but quarterly earnings will post -1.00% year-over-year. Quarterly sales are estimated to shrink -5.50% in year-over-year returns.

Intellia Therapeutics Inc (NTLA) Top Institutional Holders

419 institutions hold shares in Intellia Therapeutics Inc (NTLA), with institutional investors hold 92.00% of the company’s shares. The shares outstanding are 89.55M, and float is at 87.49M with Short Float at 12.54%. Institutions hold 91.00% of the Float.

The top institutional shareholder in the company is ARK Investment Management, LLC with over 9.95 million shares valued at $314.58 million. The investor’s holdings represent 11.24% of the NTLA Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 8.19 million shares valued at $333.79 million to account for 9.25% of the shares outstanding. The other top investors are Blackrock Inc. which holds 8.05 million shares representing 9.10% and valued at over $328.48 million, while State Street Corporation holds 3.95% of the shares totaling 3.49 million with a market value of $142.44 million.

Intellia Therapeutics Inc (NTLA) Insider Activity

A total of 1 insider transactions have happened at Intellia Therapeutics Inc (NTLA) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by Sepp-Lorenzino Laura,the company’sEVP, Chief Scientific Officer. SEC filings show that Sepp-Lorenzino Laura sold 2,275 shares of the company’s common stock on Jan 08 at a price of $28.87 per share for a total of $65682.0. Following the sale, the insider now owns 43927.0 shares.

Intellia Therapeutics Inc disclosed in a document filed with the SEC on Jan 03 that LEONARD JOHN M (President and CEO) sold a total of 19,223 shares of the company’s common stock. The trade occurred on Jan 03 and was made at $29.46 per share for $0.57 million. Following the transaction, the insider now directly holds 0.85 million shares of the NTLA stock.

Still, SEC filings show that on Jan 03, Lebwohl David (EVP, Chief Medical Officer) disposed off 5,843 shares at an average price of $29.46 for $0.17 million. The insider now directly holds 54,372 shares of Intellia Therapeutics Inc (NTLA).

Intellia Therapeutics Inc (NTLA): Who are the competitors?

The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -90.47% down over the past 12 months. Plandai Biotechnology Inc. (PLPL) that is -33.33% lower over the same period.